About e2v Biosensors
e2v biosensors limited is a wholly owned subsidiary of e2v technologies plc (www.e2v.com) focused on developing and commercialising a series of novel, convenient-to-use protein detection tests for use in healthcare and related markets. The e2v biosensor technology combines an antibody capture step with a Surface Enhanced Resonance Raman Spectroscopy signal and offers the simplicity of a disposable plastic chip with an assay design that avoids the need for labelling the sample.
In 2003, e2v technologies initiated a strategic R&D programme based on its novel, biosensor platform. Following significant investment in house, this has led to the formation in 2006 of a new subsidiary company called e2v biosensors limited (“e2v biosensors”). e2v biosensors is developing and commercialising a series of novel, convenient-to-use products for protein detection using simple, rapid, highly sensitive, reproducible and accurate methods.
Dr Paul Rodgers of Ithaka Life Sciences (www.ithaka.co.uk) was appointed as interim CEO of e2v biosensors in May 2008.
e2v biosensors has identified Point of Care diagnostics was identified as the principal market opportunity for its technology. A highly sensitive Point of Care test for the cardiac biomarker Troponin is under development as a demonstrator of the e2v technology. Other opportunities in drug development and life sciences research have also identified.
The company is seeking partners for commercialisation of its technology and is interested in receiving contacts from organisations wishing to participate in the development of novel protein detection tests.